VISIT US IN CHICAGO JUNE 2-4 AT BOOTH 2073!

Dr. Rini on Standards of Care for Advanced RCC

Brian I. Rini, MD
Published: Thursday, Jul 14, 2011

Brian I. Rini, MD, a staff member in the Department of Solid Tumor Oncology at the Taussig Cancer Institute at Cleveland Clinic in Ohio, discusses the lack of a current standard of care for advanced renal cell carcinoma. He describes how trials, such as the AXIS 1032 phase III trial comparing axitinib to sorafenib in the second-line setting for metastatic renal cell carcinoma (mRCC), can help improve treatment options for the disease.
Brian I. Rini, MD, a staff member in the Department of Solid Tumor Oncology at the Taussig Cancer Institute at Cleveland Clinic in Ohio, discusses the lack of a current standard of care for advanced renal cell carcinoma. He describes how trials, such as the AXIS 1032 phase III trial comparing axitinib to sorafenib in the second-line setting for metastatic renal cell carcinoma (mRCC), can help improve treatment options for the disease.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections: New York GU™: 10th Annual Interdisciplinary Prostate Cancer Congress® and other Genitourinary MalignanciesMay 30, 20181.5
Community Practice Connections™: Advancing RCC: A Focused Assessment of Recent Paradigm Shifts and Next Steps to Move the Field ForwardMay 30, 20181.5
Publication Bottom Border
Border Publication
x